NZ520547A - A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3 - Google Patents

A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3

Info

Publication number
NZ520547A
NZ520547A NZ520547A NZ52054701A NZ520547A NZ 520547 A NZ520547 A NZ 520547A NZ 520547 A NZ520547 A NZ 520547A NZ 52054701 A NZ52054701 A NZ 52054701A NZ 520547 A NZ520547 A NZ 520547A
Authority
NZ
New Zealand
Prior art keywords
cdr2
cdr3
amino acid
tyr
binding molecule
Prior art date
Application number
NZ520547A
Other languages
English (en)
Inventor
Hansjoerg Adam
Lothar Farber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ520547A publication Critical patent/NZ520547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ520547A 2000-03-30 2001-03-28 A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3 NZ520547A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
NZ520547A true NZ520547A (en) 2005-04-29

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ520547A NZ520547A (en) 2000-03-30 2001-03-28 A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3

Country Status (18)

Country Link
US (2) US20050226872A1 (https=)
EP (1) EP1268553A1 (https=)
JP (1) JP2003528890A (https=)
KR (2) KR20020084107A (https=)
CN (1) CN1416432A (https=)
AU (2) AU4651601A (https=)
BR (1) BR0109549A (https=)
CA (1) CA2401249A1 (https=)
GB (1) GB0007911D0 (https=)
HU (1) HUP0301846A3 (https=)
IL (1) IL151089A0 (https=)
NO (1) NO20024579L (https=)
NZ (1) NZ520547A (https=)
PL (1) PL357014A1 (https=)
RU (1) RU2286797C2 (https=)
SK (1) SK13892002A3 (https=)
WO (1) WO2001072845A1 (https=)
ZA (1) ZA200207736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502593A (ja) * 2001-04-06 2005-01-27 ユニバーシティ・オブ・ブリストル ステロイド耐性患者におけるｃｄ２５結合分子の使用
CA2711843C (en) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas

Also Published As

Publication number Publication date
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
RU2002127800A (ru) 2004-03-27
NO20024579L (no) 2002-11-11
AU4651601A (en) 2001-10-08
WO2001072845A1 (en) 2001-10-04
US20090041775A1 (en) 2009-02-12
HUP0301846A3 (en) 2010-07-28
HUP0301846A2 (hu) 2003-09-29
RU2286797C2 (ru) 2006-11-10
CN1416432A (zh) 2003-05-07
ZA200207736B (en) 2003-05-08
PL357014A1 (en) 2004-07-12
SK13892002A3 (sk) 2003-05-02
JP2003528890A (ja) 2003-09-30
KR20080079702A (ko) 2008-09-01
IL151089A0 (en) 2003-04-10
NO20024579D0 (no) 2002-09-24
EP1268553A1 (en) 2003-01-02
GB0007911D0 (en) 2000-05-17
BR0109549A (pt) 2003-06-10
KR20020084107A (ko) 2002-11-04

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2024174883A (ja) 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
AU2008212004B2 (en) Method for the treatment of multiple sclerosis
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
KR20170062505A (ko) Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법
KR20130098279A (ko) 관절염 치료
CN101657215A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
KR20210046716A (ko) 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US20230043949A1 (en) Methods for the treatment of chronic pouchitis
JP2019508448A (ja) 移植片対宿主病予防の方法
JP2003528890A5 (https=)
CN117298268A (zh) 治疗或预防移植物抗宿主疾病的方法
TW202028248A (zh) 使用抗ｃｄ１２３免疫結合物之治療方法
EP4547271A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
US20020110558A1 (en) Use of CD25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
RU2318537C2 (ru) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
CN121568960A (zh) 治疗骨癌的方法
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)